Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Arch Biopartners Inc V.ARCH

Alternate Symbol(s):  ACHFF

Technology Scientific & Technical Instruments
Arch Biopartners Inc. is a portfolio-based biotechnology company focused on the development of technologies that have the potential to make a medical or commercial impact. The Company is focused on the clinical development of its drug platform in targeting dipeptidase-1 (DPEP-1) mediated organ inflammation in the lungs, liver and kidneys. Its lead drug candidate is LSALT Peptide (Metablok... see more

Recent & Breaking News (TSXV:ARCH)

Shares for Interest Debt Settlement; Grants Options

GlobeNewswire December 15, 2022

Arch Biopartners (TSXV:ARCH) welcomes Farris Smith as a Strategic Advisor

Brieanna McCutcheon  October 5, 2022

Arch Biopartners Adds Farris Smith as a Strategic Advisor

GlobeNewswire October 5, 2022

Arch Biopartners Adds Dr. David Luke as a Strategic Advisor, Clinical Trials

GlobeNewswire August 5, 2022

Arch Biopartners' (TSXV:ARCH) trial receives approval to include LSALT Peptide

Caroline Egan  February 14, 2022

Canadian Treatments for COVID-19 (CATCO) Trial Receives Approval from Health Canada to Amend Protocol to include LSALT Peptide (Metablok)

GlobeNewswire February 14, 2022

Shares for Interest Debt Settlement

GlobeNewswire February 8, 2022

Arch Biopartners (TSXV:ARCH) publishes data on lead drug candidate

Caroline Egan  February 3, 2022

Arch Scientists Publish Data on the Mechanism of Action and Efficacy of Lead Drug Candidate LSALT Peptide in the Prevention of Acute Kidney Injury

GlobeNewswire February 3, 2022

Research Ethics Board approves amendment to Canadian Treatments for COVID-19 (CATCO) Trial to include LSALT Peptide (Metablok)

GlobeNewswire January 4, 2022

Arch Biopartners' Lead Drug LSALT Peptide to Enter the Canadian Treatments for COVID-19 (CATCO) Trial

GlobeNewswire December 1, 2021

Unaware of Any Undisclosed Material Change

GlobeNewswire October 15, 2021

Arch Biopartners Provides Update on Phase II Trial for LSALT Peptide

GlobeNewswire August 5, 2021

Arch Scientists Awarded CIHR Grant to Study LSALT for the Prevention of Chronic Disease

GlobeNewswire July 14, 2021

Arch Biopartners (TSXV:ARCH) files patent application for targeting DPEP-1 mediated organ inflammation

Brieanna McCutcheon  June 10, 2021

Arch Biopartners Files New Patent Application for Novel Antibody Candidates Targeting DPEP-1 Mediated Organ Inflammation

GlobeNewswire June 10, 2021

Arch Biopartners Enters Into Worldwide License Agreement With Telara Pharma To Re-Purpose Cilastatin For The Treatment And Prevention Of Acute Kidney Injury

Globe Newswire April 15, 2021

Turkish Ministry of Health approves Arch Biopartners (TSXV:ARCH) increased patient recruitment

Brieanna McCutcheon  March 30, 2021

Turkish Ministry of Health Approves Increase in Patient Recruitment into the Phase II Trial for LSALT Peptide

GlobeNewswire March 30, 2021

Arch Biopartners (TSXV:ARCH) enters exclusive license agreement for topical wound treatment

Simon Druker  March 24, 2021